DSM Integrated Annual Report 2020

2 Alternative performance measures

In presenting and discussing DSM’s financial position, operating results and net results, management uses certain Alternative performance measures not defined by IFRS. These Alternative performance measures (APMs) should not be viewed in isolation as alternatives to the equivalent IFRS measures and should be used as supplementary information in conjunction with the most directly comparable IFRS measures. Alternative performance measures do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies.

To provide clear reporting on the developments of the business, APM adjustments, which represent material items of income or expense, are made. These adjustments impact the EBIT(DA), operating profit, net profit, ROCE, cash provided by operating activities and EPS. A reconciliation of the Alternative performance measures to the most directly comparable IFRS measures can be found in the table Alternative performance measures.

The APM adjustments to net profit, as included in the APMs, can be specified as follows:

 

 

2020

 

2019

 

 

 

 

 

APM Adjustments (continuing operations)

 

 

 

 

- Acquisitions / divestments

 

52

 

13

- Restructuring

 

103

 

64

- Other

 

11

 

17

- Impairments of PPE and intangible assets

 

101

 

23

- Income tax related to adjustments

 

(54)

 

(26)

- Adjustments to result from associates and joint ventures

 

41

 

(28)

Total APM adjustments (income) / expense

 

254

 

63

2020

The APM adjustments in 2020 are listed below:

  • Acquisition and divestment costs of €52 million relate mainly to the acquisition of Glycom, CSK and Erber Group
  • Restructuring costs of €103 million relate to restructuring projects (mainly Fit for Growth within Nutrition and Agile to grow within Materials) together with the redundancy schemes associated with the dismissal of employees and costs of termination of contracts
  • Impairments of property, plant and equipment (PPE) and intangible assets of €101 million and the other APM adjustment of €11 million relates to an impairment of €56 million of DSM Bio-based Products & Services, owing to an expected subdued market outlook for biofuels which led to insufficient expected future cash flows and an impairment of €56 million relating to DSM Advanced Solar on its solar assets following the sale to Covestro AG
  • APM adjustments to the result from associates and joint ventures of €41 million mainly relate to the joint venture POET-DSM, following the decision to mothball the second-generation bio-ethanol plant in Emmetsburg (Iowa, USA) and includes DSM’s equity-accounted share in the impairment loss recognized by the joint venture (€74 million), the impairment of the associated intangible assets (€11 million) and the related tax benefit (-€28 million)

2019

The APM adjustments in 2019 are listed below:

  • Acquisition and divestment costs of €13 million relate mainly to the acquisition of Yimante, Andre Pectin and CSK
  • Restructuring costs of €64 million relate to project costs of the restructuring projects together with the redundancy schemes associated with the dismissal of employees and costs of termination of contracts
  • The other APM adjustment of €17 million relates to the provision for soil cleaning within Corporate Activities
  • Impairments of property, plant and equipment (PPE) and intangible assets of €23 million relate mainly to a development project of DSM Nutritional Products and the impairment of an investment project within DSM Food Specialties
  • APM adjustments to the result from associates and joint ventures of €28 million mainly relate to the step-up to the fair value of the associate Andre Pectin prior to the acquisition
Alternative performance measures (continuing operations)

 

 

2020

 

2019

 

 

 

 

 

Operating profit

 

662

 

872

Depreciation, amortization and impairments

 

706

 

585

EBITDA

 

1,368

 

1,457

 

 

 

 

 

APM adjustments to EBITDA:

 

 

 

 

- Acquisitions / divestments

 

52

 

13

- Restructuring

 

103

 

64

- Other

 

11

 

17

Total APM adjustments

 

166

 

94

Adjusted EBITDA

 

1,534

 

1,551

 

 

 

 

 

Operating profit

 

662

 

872

 

 

 

 

 

APM adjustments to Operating profit:

 

 

 

 

- APM adjustments to EBITDA

 

166

 

94

- Impairments of PPE and Intangible assets

 

101

 

23

Total APM adjustments

 

267

 

117

Adjusted operating profit

 

929

 

989

 

 

 

 

 

Net profit from continuing operations

 

457

 

689

 

 

 

 

 

APM adjustments to:

 

 

 

 

- Operating profit

 

267

 

117

- Result relating to associates / joint ventures

 

41

 

(28)

Income tax related to APM adjustments

 

(54)

 

(26)

Total APM adjustments

 

254

 

63

Adjusted net profit from continuing operations

 

711

 

752

 

 

 

 

 

Profit attributable to non-controlling interests

 

2

 

(5)

Dividend on cumulative preference shares

 

(7)

 

(8)

Adjusted net profit from continuing operations available to holders of ordinary shares

 

706

 

739

Below table reflects the earnings per share (EPS) related to continuing operations and to total earnings including discontinued operations.

 

 

2020

 

2019

in €

 

Continuing operations

 

Total

 

Continuing operations

 

Total

 

 

 

 

 

 

 

 

 

Earnings per share (EPS)

 

 

 

 

 

 

 

 

Average number of ordinary shares outstanding (x 1,000)

 

 

 

171,536

 

 

 

175,731

Effect of dilution due to share options (x 1,000)

 

 

 

896

 

 

 

1,088

Adjusted average number of ordinary shares outstanding (x 1,000)

 

 

 

172,432

 

 

 

176,819

 

 

 

 

 

 

 

 

 

Net profit available to holders of ordinary shares

 

452

 

499

 

677

 

750

Adjusted net profit available to holders of ordinary shares

 

706

 

760

 

739

 

815

 

 

 

 

 

 

 

 

 

Net basic EPS

 

2.64

 

2.91

 

3.85

 

4.27

Net diluted EPS

 

2.62

 

2.89

 

3.83

 

4.24

Adjusted net basic EPS

 

4.12

 

4.43

 

4.21

 

4.64

Adjusted net diluted EPS

 

4.09

 

4.41

 

4.18

 

4.61

Alternative performance measures

 

 

2020

 

2,019

 

 

 

 

 

Capital employed

 

 

 

 

Intangible assets

 

4,455

 

3,515

Property, plant and equipment

 

3,774

 

4,040

Investment grants / drawing rights

 

(112)

 

(96)

Inventories

 

1,879

 

2,019

Current receivables

 

1,488

 

1,698

Included discontinued operations

 

-

 

(883)

Capital employed at 31 December

 

9,697

 

8,428

 

 

 

 

 

Average capital employed

 

 

 

 

Capital employed at 1 January

 

8,428

 

7,527

Capital employed at 31 March

 

8,422

 

8,021

Capital employed at 30 June

 

9,024

 

7,850

Capital employed at 30 September

 

9,018

 

8,415

Capital employed at 31 December

 

9,697

 

8,428

Average capital employed

 

8,918

 

8,048

Adjusted operating profit, continuing operations

 

929

 

989

ROCE in %, continuing operations

 

10.4

 

12.3

 

 

 

 

 

Cash provided by operating activities

 

1,494

 

1,385

Cash impact APM adjustments

 

87

 

57

Capital expenditure

 

(609)

 

(627)

Payments regarding drawing rights

 

(17)

 

(14)

Adjusted net operating free cash flow

 

955

 

801

APM
Alternative performance measures
EPS
Earnings per share
IFRS
International Financial Reporting Standards
PPE
Personal Protective Equipment; also Property, Plant and Equipment
Return on capital employed (ROCE)
Adjusted operating profit from continuing operations as a percentage of average capital employed.